Scott A. Holmes Sells 2,830 Shares of Keryx Biopharmaceuticals (KERX) Stock
Keryx Biopharmaceuticals (NASDAQ:KERX) CFO Scott A. Holmes sold 2,830 shares of the company’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $4.81, for a total transaction of $13,612.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Keryx Biopharmaceuticals (NASDAQ:KERX) traded down $0.09 on Wednesday, reaching $4.63. 834,756 shares of the company traded hands, compared to its average volume of 1,148,169. The firm has a market capitalization of $583.00, a PE ratio of -3.09 and a beta of 4.93. The company has a quick ratio of 3.76, a current ratio of 4.46 and a debt-to-equity ratio of 13.95. Keryx Biopharmaceuticals has a 1 year low of $4.33 and a 1 year high of $8.38.
Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The company had revenue of $15.00 million during the quarter, compared to analyst estimates of $18.88 million. Keryx Biopharmaceuticals had a negative net margin of 323.92% and a negative return on equity of 10,954.62%. The company’s revenue was up 138.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.39) earnings per share. sell-side analysts predict that Keryx Biopharmaceuticals will post -1.35 earnings per share for the current year.
Several analysts recently issued reports on the stock. ValuEngine cut shares of Keryx Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, November 10th. Zacks Investment Research raised shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, December 1st. Finally, Stifel Nicolaus cut their price target on shares of Keryx Biopharmaceuticals from $7.00 to $5.00 and set a “hold” rating on the stock in a report on Wednesday, November 8th. One analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company’s stock. Keryx Biopharmaceuticals presently has an average rating of “Hold” and a consensus price target of $7.44.
ILLEGAL ACTIVITY WARNING: “Scott A. Holmes Sells 2,830 Shares of Keryx Biopharmaceuticals (KERX) Stock” was reported by Watch List News and is the property of of Watch List News. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://www.watchlistnews.com/scott-a-holmes-sells-2830-shares-of-keryx-biopharmaceuticals-kerx-stock/1835528.html.
About Keryx Biopharmaceuticals
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.